Publications by authors named "Dylan A Farnsworth"

Claim this Profile
D
Drug tolerance and persistence to EGFR inhibitor treatment are mediated by an ILK-SFK-YAP signaling axis in lung adenocarcinoma.
Rocky Shi, Dylan A Farnsworth, Christopher A Febres-Aldana, Justine L M Chow, Ravinder Sheena

Oncogene· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extracellular Vesicles from Lung Adenocarcinoma Cells Induce Activation of Different Cancer-Associated Fibroblast Subtypes.
Jessica Angelina Trejo Vazquez, Rebecca Towle, Dylan Andrew Farnsworth, Masih Sarafan, William Wallace Lockwood

Biomedicines· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression.
Dylan A Farnsworth, Yusuke Inoue, Fraser D Johnson, Georgia de Rappard-Yuswack, Daniel Lu

NPJ Precis Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of a small molecule inhibitor of disulfide reductases that induces oxidative stress and lethality in lung cancer cells.
Fraser D Johnson, John Ferrarone, Alvin Liu, Christina Brandstädter, Ravi Munuganti, Dylan A Farnsworth

Cell Rep· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer.
Dylan A Farnsworth, Yankuan T Chen, Georgia de Rappard Yuswack, William W Lockwood

Cells· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis